The aim of this study was to compare the effects of ramipril and nitrendipine chronic treatment on urinary albumin excretion (UAE) in hypertensive patients with type II non-insulin-dependent diabetes mellitus (NIDDM) and impaired renal function. A 2-year, prospective, randomised study was conducted on 51 men with a diastolic blood pressure (DBP) у95 and р105 mm Hg, stable NIDDM, serum creatinine between 1.6 and 3.0 mg/dl and persistent UAE Ͼ300 and Ͻ2000 mg/24 h. After a 3-month preliminary observation period, during which patients began a low-protein, low-sodium diet, and a subsequent 4-week run-in period on placebo, patients were randomly treated with ramipril 5 mg or nitrendipine 20 mg for 2 years. Both drugs similarly reduced BP without affecting glucose homeostasis. In the ramipril group
Introduction
Systemic hypertension has been shown to accelerate diabetic nephropathy in both the experimental 1 and human context. 2 Clinical studies have demonstrated that in hypertensive patients with either type I or type II diabetes, antihypertensive therapy is useful in slowing the progression of diabetic renal disease assessed by a reduction in the urinary albumin excretion (UAE) and decline in the glomerular filtration rate, [3] [4] [5] although antihypertensive agents do not seem to be equally effective in this regard. 6 Several long-term studies have shown that angiotensin-converting enzyme inhibitors (ACE-I) have a beneficial effect in reducing UAE and preserving renal function whether the patient has type I or type II diabetes and whether or not the patient has microalbuminuria or clinically apparent proteinuria. [7] [8] [9] [10] [11] [12] [13] [14] The effects of calcium channel blockers (CCB) on proteinuria and on the progression of renal disease are more controversial. In animal models, CCB have been shown to attenuate glomerular damage and proteinuria. 15, 16 In human subjects, certain classes of UAE significantly decreased after only 3 months of treatment, whereas in the nitrendipine group a significant although lesser reduction in UAE was observed only after 1 year. During the second year the UAE% change was not statistically different between the two treatments. Serum creatinine and creatinine clearance showed no significant change with both drugs. The progression of renal insufficiency as assessed by the rate of reduction of creatinine clearance over the 2 years of the study was similar in the ramipril and the nitrendipine groups. In conclusion both ramipril and nitrendipine were associated with a decrease in UAE although such a reduction was earlier and more marked with ramipril. The decline of renal function did not differ significantly between the two treatments.
CCB, specifically the papaverine (verapamil) and benzothiaprine (diltiazem) derivatives, effectively decreased UAE and attenuated the progression of renal dysfunction. [17] [18] [19] [20] Conversely, most studies with the dihydropyridine CCB nifedipine demonstrated no effect or increases in UAE. [18] [19] [20] [21] 22 However, caution is needed in interpreting the results of these studies, which have been relatively short in duration. Indeed, some recent comparisons of the long-term effect of ACE-I and dihydropyridine CCB in diabetic patients with incipient nephropathy have shown that both drugs decreased albuminuria with no difference in their effects. [23] [24] [25] [26] This suggests that the duration of follow-up should be sufficiently long in order to fully detect the drug effect on renal function.
The present prospective trial aimed to compare the influence of long-term monotherapy with the ACE-I ramipril 27 and the dihydropyridine CCB nitrendipine 28 on UAE in hypertensive patients with type II, non-insulin-dependent diabetes mellitus (NIDDM) and impaired renal function.
Subjects and methods
This was a 2-year prospective, randomised, controlled trial with parallel groups. Eligible subjects were mild essential hypertensive patients (diastolic blood pressure (DBP) у95 and р105 mm Hg with type II NIDDM (National Diabetes Data Group Criteria) 29 and concomitant impaired renal function, defined by a serum creatinine concentration ranging between 1.6 to 3.0 mg/dl. In order to eliminate confounding factors due to gender only men were included. In the trial design patients were required to have: (1) a stable glucose metabolic state, defined as absence of glycosuria, glycosilated haemoglobin (HbA 1c ) Ͻ7.8% and no need to change antidiabetic treatment for the last 3 months; (2) a variation in plasma creatinine less than 40% during a 3-month preliminary observation period; (3) a persistent UAE Ͼ300 mg/24 h in three distinct 24-h urine collections during a 3-month preliminary observation period; (4) a good general condition.
Patients were excluded from the study if they had cardiac or hepatic dysfunction, ankle oedema or proteinuria greater than 2000 mg/24 h. Patients with a history of intolerance or failure to respond to ACE-I or CCB were likewise excluded.
At the end of a 3-month preliminary observation period, 117 eligible patients were considered for entering the study. Each patient gave informed consent to participate in the study, whose protocol was also approved by the local Ethical Committee.
After inclusion in the study, patients entered a 4-week placebo period, during which any antihypertensive drug was discontinued. Patients were encouraged to continue a low protein (0.6-0.7 g protein/kg body weight per day), low sodium (60-100 mol/sodium per day), hypoglucidic diet, that they also followed during the preliminary observation phase. A caloric supply of 32 to 35 kcal/kg/day was advised. Concomitant treatment consisted of oral antidiabetic drugs and allopurinol when needed.
At the end of the placebo period, 107 patients, aged 45-71 years (mean age: 58±1 yr) were responding to the following inclusion criteria: DBP у95 and р105 mm Hg, UAE Ͼ300 and Ͻ2000 mg/24 h in two consecutive 24-h urine collections, HbA 1c Ͻ7.8%.
They were randomly allocated to ramipril (54 patients) or nitrendipine (53 patients) treatment. The initial dosages of ramipril and nitrendipine were 2.5 and 10 mg once daily respectively and these were increased in all patients to 5 mg o.d. and 
10 mg twice daily after 1 month of therapy. Those patients who had not reached the goal therapy (DBP Ͻ90 mm Hg or a decrease of Ͼ10 mm Hg with respect to placebo) after 3 months of treatment were withdrawn from the study. Such a decision was taken as we wanted to continue monotherapy in order to avoid possible confounding factors due to the addition of another hypotensive drug, and we considered it unethical to maintain our patients without appropriate BP control for 2 years. During the first 3 months of the study, monthly surveillance was performed, including a complete morning clinical examination in which systolic BP (SBP), DBP, heart rate (HR) and fasting glycaemia were assessed. BP was measured on the patient's same arm three times after 5-min resting in a sitting position (at consecutive 2-min intervals), by using a standard mercury sphygmomanometer (Korotkoff I and V) with the appropriately sized cuff. The actual BP value was considered as the average of the three measurements.
From 3 months onwards patients were checked every 3 months during the first year and every 6 months during the second year. At each examination, BP, HR, body weight, fasting glycaemia, 24-h glycosuria, HbA 1c , serum creatinine, creatinine clearance and 24-h UAE were evaluated.
Chemical analyses of serum and urine were performed by standard clinical laboratory technique. HbA 1c concentrations were determined by high performance liquid chromatography. UAE was measured on two 24-h urine collections within a week. Patients were advised to have minimal physical activity. Clear instructions were given on how to collect urine samples and patients were asked to bring complete samples to the clinic with them. UAE was evaluated by radioimmunoassay (RIA). Renal function was evaluated using creatinine clearance. The mean decline in creatinine clearance (ml/min/month) was calculated. Compliance with diet was evaluated by 24-h urinary urea excretion and dietary interview in each patient at each clinic visit. Information on adverse events was elicited by non-specific questioning.
All data are expressed as means ± s.d., with the exception of 24-h UAE, which is expressed as mean ± confidence interval (95%). The homogeneity check of patient distribution between the two treatment 
Results
A total of 107 patients were randomly assigned to ramipril (n = 54) or nitrendipine (n = 53) treatment and 56 patients dropped out from the study during the 2-year period (Table 1) . These patients were equally distributed between the ramipril (n = 28) and the nitrendipine group (n = 28). No patients were excluded from the study on the grounds of albuminuria Ͼ2000 mg/24 h during the 2-year study period. The main adverse events leading to withdrawal were cough (2) and headache (1) in the ramipril group, headache (1), ankle oedema (3) and flushing (1) in the nitrendipine group. All side effects were completely reversible after discontinuation of treatment.
The following results only include data on the 51 patients who completed the 2-year study protocol. Their demographic and clinical characteristics at randomisation are shown in Table 2 . Although before randomisation patients were not stratified according to the degree of renal impairment, serum creatinine and creatinine clearance were not statistically different between the two treatment groups. They were also comparable with regard to duration of hypertension and diabetes and baseline values of BP, HR, body weight, UAE, blood glucose and HbA. The main results of the study are reported in Table 3 .
Both ramipril and nitrendipine significantly lowered mean SBP and DBP over the 2-year treatment period (Figure 1) , without affecting HR. In both treatment groups the SBP/DBP reductions were already evident at 3 months (−11/−13% with ramipril and −10/−11% with nitrendipine, P Ͻ0.05 vs placebo for both comparisons) and persisted throughout the study, being −10/−13% and −9/−10% respectively after 2 years of therapy. When a comparison was made between ramipril and nitrendipine-treated patients, no significant difference in the average BP levels was observed at any time during the study. No patient required therapy to be discontinued as a result of symptomatic hypotension.
UAE significantly decreased after only 3 months of treatment in the ramipril group (from 792.2 ± 40.6 to 609.5 ± 47.33 mg/24 h, P Ͻ0.05). A further decrease was observed after 6 months of ramipril treatment (to 515.4 ± 30.1 mg/24 h, P Ͻ0.01 vs placebo); thereafter UAE values tended to remain stable over time, being 536.2 ± 32.6 mg/24 h, P Ͻ0.01 vs placebo, at 2 years. Instead, in the nitrendipine-treated patients, a significant decrease in UAE was observed only after 1 year of treatment (from 768.4 ± 39.2 to 603.8 ± 32.4 mg/24 h, P Ͻ0.05 vs placebo) and was less pronounced than that induced by ramipril. UAE persisted substantially unchanged subsequently, being 618.3 ± 30.2 at 2 years. Considering the statistical power of our comparison, a posterior analysis showed a very large effect size that brought the mean power to values Ͼ90%.
To compare the effects of the two drugs on UAE, the percentage UAE change during each treatment was also evaluated (Figure 2 ). Both ramipril and nitrendipine reduced UAE. Ramipril, however, significantly lowered UAE from the third month onwards; the percent decrease was more evident during the first year of observation, a minimal steady decrease being observed during the second year. Instead, with nitrendipine the percentage UAE change reached statistical significance only after 1 year of treatment and was less marked as compared to the ramipril-induced UAE decrease. During the second year of observation, the UAE% changes were not statistically different between the two treatments.
UAE changes during therapy with both drugs were not correlated with DBP, HbA 1c , creatinine clearance and serum creatinine changes. The changes in UAE were weakly correlated with a SBP change (r = 0.39, P Ͻ0.05) in the nitrendipine but not in the ramipril group.
Serum creatinine levels did not significantly change from baseline during the 2-year treatment with both drugs, (P = 0.067 with ramipril, P = 0.062 with nitrendipine) although an increasing trend was observed (Table 3) . Likewise, creatinine clearance showed no statistical modification, (P = 0.071 with ramipril, P = 0.068 with nitrendipine) although a tendency towards a decrease was noted in both Table 3 Systolic (SBP) and diastolic (DBP) blood pressure, heart rate (HR), creatinine clearance (CC), serum creatinine (S.CREAT), glycated haemoglobin (HbA 1c ) and urinary urea nitrogen excretion (UUNE) (mean vs ± s.d.), 24-h urinary albumin excretion (UAE) (mean vs ± CI 95%), before and after treatment with ramipril (n EQ 26) and nitrendipine (n EQ 25) 
(*P Ͻ0.05; **P Ͻ 0.01).
Figure 1
Mean values of systolic (SBP) and diastolic blood pressure (DBP) in diabetic hypertensive patients treated with ramipril or nitrendipine for 24 months. **P Ͻ0.01 vs wash-out.
treatment groups (Table 3 and Figure 3 ). Considering the progression of renal failure, as assessed by the rate of reduction of creatinine clearance over the 2 years of the study, the mean decline in creatinine clearance was 0.16 ml/min/month in the ramipril group and 0.10 ml/min/month in the nitrendipine group, with no statistical difference between the two treatments.
To examine the role of BP control on the progression of renal insufficiency, SBP and DBP changes were plotted with the creatinine clearance decline, but no significant correlation was found.
No difference in dietary compliance as assessed by the evaluation of UAE (Table 3 ) and dietary interviews was found between the two treatment groups. Body weight remained substantially unchanged in all patients. Glycaemic control, as assessed by fasting blood glucose and HbA 1c concentrations, was not influenced by either treatment and no patient required changes in hypoglycaemic therapy. 
Discussion
The results of this study indicated that ramipril and nitrendipine produced similar BP lowering in the long-term treatment of hypertensive patients with type II, NIDDM and impaired renal function. Despite equivalent BP control, however, ramipril produced an earlier and greater reduction in UAE as compared to nitrendipine.
This suggests that the anti-albuminuric effect of ramipril is at least partially independent of its antihypertensive effect, thus confirming previous observations with this and other ACE-I in type II diabetic patients. 13, 14, 23, 30 Indeed, the reduction of albuminuria after ACE-I has been attributed to several additive factors, including: (a) the effects on renal haemodynamic which consists in a reduction of glomerular capillary pressure and subsequent preservation of glomeruli; 31 (b) a direct effect on mesangial cell growth 32 : ACE-I may interfere with trophic properties of Ang II to promote cellular and glomerular hypertrophy 33 or diminish the accumulation of mesangial matrix 34 ; (c) a direct effect on the glomerular basement membrane with enhancement of the barrier size-selectivity 35 ; (d) an effect on the vascular permeability. 36 Which of these factors predominates remains to be established.
Unlike previous studies which found no significant effect of dihydropyridine CCBs on UAE, 18, 21, 22, 37, 38 in our study we observed a reduction of UAE in the nitrendipine-treated patients, but such an antiproteinuric effect became statistically significant only after 1 year of treatment and was less pronounced as compared to the ramipril induced UAE reduction. This finding suggests two considerations: (a) first, the reduction in UAE from nitrendipine could be mainly attributed to the decrease in systemic BP rather than to other intrinsic effects of the drug, which is supported by the correlation between the UAE and the SBP changes that we found in the nitrendipine but not in the ramipril-treated patients. More properly, the antiproteinuric effect of CCB might be related to their effect of substantially reducing systemic arterial pressure while relaxing afferent glomerular arteriole, the changes in intraglomerular pressure and UAE depending on the balance between pre-glomerular vasodilation and systemic BP reduction. 39, 40 It is therefore possible that, if systemic BP is not lowered enough, as may be the case of most studies of normotensive diabetics with incipient nephropathy, CCBs do not reduce UAE. In this study, BP was remarkably reduced by nitrendipine, which might have accounted for its anti-albuminuric effect. This observation is consistent with previous reports that BP control is an important factor in reducing UAE in hypertensive patients with both incipient and overt nephropathy 3, 5, 24, 41, 42 ; and (b) second, the late effect of nitrendipine on UAE, which resembles our previous observation with another dihydropyridine CCB, amlodipine, 23 suggests that the duration of follow-up of intervention trials must be sufficiently long in order to fully detect the drug effect on UAE.
In this study there was no significant change in glycaemic control during the 2 years of treatment with both ramipril and nitrendipine. This suggests that the observed effects on UAE could not be explained by variations in glycaemic control.
If the hypothesis is correct that proteinuria in itself provokes renal damage by increased mesangial and interstitial flux of protein, a reduction in proteinuria would be beneficial in terms of renal protection. 34 In fact, whether the reduction in UAE is coupled with rate of decline in renal function and renal structural changes remains to be established.
In our study renal function was assessed by creatinine clearance and the decline of renal function was evaluated in terms of mean decline of creatinine clearance (ml/min/month). In order to eliminate possible misinterpretations caused by variations in protein intake 43 our patients were submitted to a low protein diet for 4 months prior to randomisation and a constant protein intake was maintained throughout the entire study. Serum creatinine concentrations and creatinine clearance did not significantly change from baseline during treatment with both ramipril and nitrendipine and no difference between the two treatments was found. The mean decline of creatinine clearance was similar in the two treatment groups. The lack of a control group on placebo did not allow us to quantify how much the antihypertensive therapy with ramipril and nitrendipine slowed down the decline of renal function in our patients as compared to untreated patients. However, in our experience, the rates of decline found in both the ramipril and the nitrendipine groups were rather low at least in comparison to that previously reported by other authors 42, 44 although the differences in the various study populations make it difficult to make such a comparison. These findings suggest that both drugs may exert a renoprotective effect with no difference between the ACE-I and the CCB. We cannot exclude, however, that the low rate of progression of renal insufficiency may be a reflection of the highly selected group of patients due to the lack of a similarly selected control group.
In conclusion the results of this study showed that in hypertensive patients with type II diabetes and impaired renal function the antihypertensive therapy with both the ACE-I ramipril and the CCB nitrendipine was able to reduce UAE, although such a reduction was earlier and more pronounced with ramipril. The progression rate of renal insufficiency did not differ significantly between the ramipril and the nitrendipine-treated patients and was rather low, which suggests that both drugs exert similar renoprotective effects.
